Apnimed, Inc. Listed Primary

What the company does

Apnimed, Inc. is a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. Its sole clinical product candidate, AD109 (Oxnimbi), is a fixed-dose, anti-apneic neuromuscular modulator combining an anti-muscarinic and a selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA). Based on results from two registrational Phase 3 trials, the company submitted an NDA for Oxnimbi to the FDA in April 2026, which was accepted for review in July 2026 with a PDUFA goal date of February 28, 2027.

Use of proceeds

The company estimates net proceeds of approximately $173.6 million from the offering (or approximately $200.4 million if the underwriters' option is exercised in full), based on the $16.00 per share IPO price. It intends to use the net proceeds, together with existing cash, to fund approximately $237.8 million toward the regulatory approval process and, if approved, the commercial launch of Oxnimbi for the treatment of OSA, with the remaining proceeds to fund research and development for additional product candidates, working capital, and other general corporate purposes.

Underwriters

Extracted from 424B4 0001193125-26-328422, filed Jul 31, 2026 and verified against that filing text.

Key risk factors

• Ongoing operating losses

  “We are a late stage clinical pharmaceutical company and have incurred significant operating losses since our inception and we expect to incur significant operating losses for the foreseeable future. We may never become profitable and, if profitability is ever achieved, we may not be able to sustain it.”

• Going concern doubt

  “There is substantial doubt about our ability to continue as a going concern.”

• Need for substantial additional funding

  “Even if this offering is successful, we will require substantial additional funding in order to finance operations. If we are unable to raise capital when needed, or on acceptable terms, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.”

• Dependence on a single product candidate

  “Our business depends on the success of our sole clinical product candidate, Oxnimbi, which has completed Phase 3 clinical trials. If we are unable to obtain regulatory approval for or successfully commercialize Oxnimbi, or are significantly delayed in doing so, our business will be materially harmed.”

• FDA approval risk

  “The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable and the FDA or comparable foreign authorities may disagree with our regulatory plans, and if we are ultimately unable to obtain regulatory approval for Oxnimbi or any future product candidates, our business will be substantially harmed.”

• Side effects and safety risks

  “The use of Oxnimbi or any future product candidates, could be associated with side effects, such as insomnia, AEs or other properties or safety risks that could delay or prevent regulatory approval, limit our market acceptance, if approved, or result in significant negative consequences following marketing approval.”

• Concentrated stockholder control

  “Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.”